The re6purposing of the anti6anginal drug perhexiline (PHX) has resulted in symptomatic improvements in heart failure (HF) patients. The inhibition of carnitine palmitoyltransferase61 (CPT61) has been proposed as the primary mechanism underlying the therapeutic benefit of PHX. This hypothesis is contentious.
We reviewed the primary literature and patent landscape of PHX from its initial development in the 1960s through to its emergence as a drug beneficial for HF. We focused on its physico6chemistry, molecular targets, tissue accumulation and clinical dosing.
Dogma that the beneficial effects of PHX are due primarily to potent myocardial CPT61 inhibition is not supported by the literature and all available evidence point to it being extremely unlikely that the effects of PHX occur via this mechanism. • In contrast to recent dogma, we propose that it is unlikely that the therapeutic benefit of perhexiline in patients with HF is due, in large part, to the inhibition of CPT61.
• All available data suggests that PHX is a drug of low potency, low specificity and low selectivity that interacts with multiple surface membrane ion channels and other intracellular components that impinge on cellular metabolism and the generation of reactive oxygen species (ROS).
• The possibility that effects of PHX on CPT61 underpin disproportionately large effects on myocardial function cannot be excluded, especially given the massive accumulation of PHX in myocardial tissue.
• A scheme is described that considers the pleiotropic effects of PHX via the inhibition of surface membrane ion channels and its accumulation in mitochondrial membranes.
• The combined action of PHX on multiple targets throughout the cardiovascular system probably underpins the symptomatic improvements in HF patients. strategies that aim to target more 'myocardially6focused' elements including the drivers of progressive contractile and arrhythmogenic events that occur cardiac cells 265 and even approaches that replace or repair damaged myocardium. 6 We have previously described normal myocardial cell signaling in terms of the synchronization of coupled systems. 769 For example, there is functional integration between cellular ion fluxes and metabolism in which the dynamic cycling of intracellular Ca 2+ is critically modulated by ATP6dependent processes, and many events in ATP synthesis are Ca 2+ 6dependent. Consequently, the functional deterioration of the myocardium in long6term cardiac diseases such as HF is associated with the progressive desynchronization within and between numerous linked processes. Using the example above, disease6linked derangement in Ca 2+ signaling, which is considered a major feature of HF pathogenesis, impacts on ATP bioavailability and vice versa. Important problems in developing new therapeutic approaches though include the limitations of rational drug design and sometimes prohibitory regulatory and financial barriers which have led to creative solutions for finding new niches for existing drugs in the clinical landscape. 4, 19623 'Repositioning', 'repurposing' and 'reappropriating' have become buzzwords in the contemporary drug development framework.
In this article, we consider some of these issues relating to perhexiline (PHX; 26 (2, 26 dicyclohexylethyl)piperidine), a drug reappropriated from the treatment of angina pectoris (AP) and reported to be a clinically useful drug in the management of HF. , its contraindications, withdrawals and now its emergence in treating HF has been comprehensively reviewed previously. 15, 18, 36 However, its mechanism of action remains contentious and here we consider, with specific reference to the patent landscape, how the apparent disconnect between the measureable clinical benefits of PHX in HF and the molecular underpinnings of its actions can be reconciled.
The hallmark metabolic dysfunction in HF is the intrinsic shift from FAO (aerobic) to glucose is the predominant isoform in the heart and exhibits a lower affinity for its substrate carnitine than CPT61A (approximately 156fold) but is more sensitive to inhibition by the endogenous inhibitor malonyl co6A inhibition than CPT1A. 49 CPT61 catalyzes the formation of acyl carnitine, via the transfer of the acyl group of a long6chain fatty acyl6CoA from coenzyme A to carnitine 50 . Acyl carnitine subsequently transfers from the cytosol into the mitochondrial inter6membrane space to undergo CPT626catalyzed conversion back to acyl6CoA which undergoes catabolic beta6oxidation in the mitochondrial matrix to yield acetyl6CoA which then enters the TCA cycle (Figure 1 ). In principle therefore, CPT61 inhibition, which is mediated by of malonyl Co6A levels (Figure 1 ), reduces mitochondrial import and oxidation of fatty acids, promotes glycolysis via reduced acetyl6CoA production and decreases ROS and lactate accumulation (Figure 1 ) albeit at the expense of ATP production. One approach to therapeutically target CPT61 activity is the development of heterocyclic and piperidine compounds that inhibit malonyl6CoA decarboxylase (MCD) which leads to an accumulation of malonyl6CoA 51, 52 , the endogenous inhibitor of CPT61
( Figure 1) . 53 We return to the subject of malonyl6CoA inhibition of CPT61, and the implications for adjunctive PHX6mediated inhibition, in section 4.
However, in the context of treating chronic myocardial dysfunction, it is the direct pharmacologic inhibition of CPT61 that has captured the imagination. , has yet to be fully established. Moreover, although these investigations evidence beneficial changes in the phosphocreatine/ATP ratio which suggest generalized improvements in cardiac energetics, in their study of DCM patients Beadle failed to find evidence of altered cardiac substrate utilization 56 . This finding is at odds with the principal dogma of earlier studies on PHX that its main effect is to promote the shift from FAO to glycolysis. 25, 29, 58, 59 It is necessary therefore to harmonize the therapeutic benefit of PHX with its mechanism of action and in sections 3 to 6 we address this issue by reference to the patent literature and the physico6chemical determinants of CPT61 inhibition. of its ability to shift metabolism in the heart from free fatty acid metabolism to glucose, which is more energy efficient", but it is striking that none of these patents claim that the clinical benefit of PHX is because of CPT61 inhibition.
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However, the CPT616centricity of the proposed mechanism of PHX action persists and a recent patent filing from the University of Aberdeen seeks to protect intellectual property (IP) around a fluorinated PHX6derivative useful for treating a very broad range of "disorders that are ameliorated by the inhibition of carnitine palmitoyltransferaseNN". 64 With regard to the progression of HF being a consequence of the deterioration of linked systems (see section 1), it is interesting to note that the patent on PHX effect in ischaemic and non6ischaemic HF 61 states that "metabolic manipulation with PHX is effective in modifying not an inciting influence, but rather the common programme of the chronic heart failure". It is plausible therefore that the metabolic dysfunction in HF is secondary to the abnormality in some other linked system and that PHX may be useful in modifying the chronic metabolic remodelling associated with HF progression and not in preventing disease onset. , the likelihood of PHX binding multiple targets (1) makes it impossible at present to assign the relative contributions of PHX modulation of individual targets to the downstream effects. As has been noted previously, these issues relating to 'holistic' assessments of drug action are presently beyond the resolution of contemporary assays.
22
On the basis of Kennedy's early work on CPT1 inhibition by PHX
71
, the review literature on PHX perpetuates the idea that the primary mechanism of action the drug is through CPT61 inhibition (for example, "the identification of CPT61 as perhexiline's major biochemical site of inhibition"
15
). Given the paucity of supporting data, the evidence base for this assertion is not convincing (Table 1) .
PHX shares common properties with other Na + 6, K + 6 and Ca 2+ 6 ion channel blockers, many of which are recognized anti6arrhythmic drugs (Table 2) , including its appreciable hydrophobicity and an ionizable nitrogen which is positively charged at neutral pH (7.4) . In this regard, PHX is chemically different to etomoxir, which is an exemplar CPT inhibitor 49 and in a quasi6exhaustive review of CPT inhibitor chemistry, PHX, oxfenicine (where the concluded that in view of PHX's extremely weak inhibition of CPT61 it was "highly questionable that the effects are due to CPT1 inhibition". 49 The chemical properties of PHX would also suggest relatively poor selectivity and specificity. 74 This is corroborated by the data in Table 1 which emphasizes the multiplicity of PHX targets and importantly, all available data point to PHX exerting its potent effect on CPT61 (Table 1) . However, it is recognized that functional pleiotropy (i.e. drug promiscuity), which we have previously considered as 'magic shotguns' versus 'magic bullets' 75 , can be beneficial. 76 This is discussed this further in section 7.
In consideration of the other reported targets of PHX ( with a recent study suggesting that malonyl6CoA produces a 33% inhibition of CPT61 activity in resting (non6stimulated) muscle. 77 However, it may be important that the actions of PHX on CPT61 are mechanistically different to those of malonyl co6A and oxfenicine (IC 50 of CPT61 inhibition = 11 SM 78 ) and it has been suggested that PHX acts at a protected mitochondrial site not amenable to proteolysis i.e. in the plane of the membrane.
15,
71, 79 It is also intriguing that the specific counterion used in the preparation of the clinical formulation of a drug may have a profound impact on its physico6chemical properties, including logP. 80 This is especially pertinent for maleate which has been shown to directly influence cellular metabolism via promoting the utilization of glucose and the accumulation of fatty acids. 81, 82 The contribution of the maleate 'counterion' to the effects attributable to PHX, especially in the context of altered metabolism, warrants further investigation. 83 Recent proteomic and metabolic studies have corroborated a complex effect of PHX on metabolism. 84, 85 In a study of mice treated for 4 weeks at steady6state PHX plasma . 49 Together these data advance the idea that the therapeutic effects of PHX may be due, in some part to metabolic modulation, but the notion of PHX being a potent inhibitor of CPT61 needs further evaluation.
To this end, the effects of PHX on reduced ROS may be more attributable to direct inhibition of NADPH oxidase (NOX2) rather than effects on cardiac energetics 86 Also,
Unger and colleagues reported that in non6ischaemic working rat hearts, "perhexiline increases myocardial efficiency by a mechanism(s) that is largely or entirely independent of its effects on CPT".
A well6known consequence of longer term (unmonitored) PHX administration (typically > 3 months) 88 is lipidosis6induced hepato6 and neuro6toxicity, hypoglycaemia and weight loss.
31,
34, 89694 However, there is now a more complete understanding of the risk factors predisposing individuals to adverse effects, including patient6specific CYP2D6 status.
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Oxidative metabolism of PHX produces mono6 and di6hydroxylated metabolites. The predominant metabolite detected in plasma 6 64 hydroxyperhexiline 6 is found at concentrations higher than PHX. 99, 100 Those individuals with CYP2D6 insufficiency ('poor metabolizers') have a reduced capacity to form this metabolite 101 and thus PHX is contraindicated in these individuals. This association between drug chirality and toxicity is also important 99, 100, 102 since there is reported stereoselectivity of (+) and (6) enantiomers to metabolism. 95, 100, 101 The asymmetry of the C2 of the piperidine ring means that PHX is administered as a racemic mixture of (+) and (6) enantiomers. The (+)6PHX enantiomer is Some of the acute effects of PHX, at least in experimental systems, are rapidly reversible. In chick embryo ventricular cells, Barry described the negative inotropic effect of PHX measured after a seven minute equilibration to reach steady state drug effects which was quickly reversed by washing out the drug. 114 However, as described in section 5, under Figure 2A ) occurs is that under these conditions the surface membrane Na + 6, K + 6 and Ca 2+ channels would also be exposed to high concentrations of drug. Since the mode of channel inhibition is through drug interaction at the cytoplasmic face of the channel and in consideration of the comparatively low IC 50 values for PHX6channel interaction (Table 1 ) these channels would be profoundly inhibited. This would result in catastrophic impact on heart rhythm and rate, effects that are conspicuously absent in PHX treated patients (although a heart rate lowering effect of PHX in other species has been reported 115, 116 ).
Cellular accumulation could however feasibly occur via a mechanism that involves PHX binding to cytoplasmic moieties which would allow the drug to partition against its concentration gradient ( Figure 2B ). It is important to note though that in these circumstances, high levels of intracellular accumulation would not translate into high levels of drug concentration, and the levels of 'free' PHX in the cytoplasm would be low ( Figure   2B ). It is possible though that low levels of 'free' PHX in the cytoplasm, which would predominantly be in the cationic form (see above), would still be sufficient to modulate surface membrane ion channel activity (Table 1) .
There is evidence of preferential association of PHX with phospholipid membranes, particularly those characterized by regional 'charge' gradients (e.g. H + gradients across localization of very high drug concentrations at these organelles. Such a mechanism could also conceivably lead to cellular 'trapping' of PHX. As to whether the protonation of PHX in the cytoplasm of the cell would lead to a buffering of H + ions and as a consequence modulate cellular pH, we believe this to be unlikely. In our view, any effect of PHX on pH normalization should remain focused on the relative balance of pyruvate6to6lactate which is dictated by the schemes outlined in Figure 1 .
From its lipophilicity profile, the partitioning of PHX into membranes (especially mitochondrial membranes once it is protonated inside the cell) is likely to be rapid and it has been reported that high concentrations of drug applied extracellularly (25 QM) affected metabolism and promoted cellular toxicity within 24h. 89 Even more striking is the direct biochemical evidence for the decreased utilization of fatty acids (by approximately 35%) in rat hearts perfused with 2 QM PHX within a one6hour experimental window. 59 The timings of these effects point to either rapid cellular accumulation or alternatively, to an acute indirect modulation of metabolism (i.e. downstream from inhibition of surface6membrane ion channels).
There are two plausible scenarios in which longer6term accumulation of PHX could modulate CPT61 and its other targets at the IC 50 s described in the literature (Table 1) . First, if CPT61 and the other targets are the target for PHX binding ( Figure 2C ). Under these conditions one would expect marked inhibition of surface membrane ion channel fluxes and, for the reasons outlined above, this is unlikely to occur . Specifically with regards CPT61 though, the scheme described in Figure 2C may seem unlikely because of the endogenous competition from the much more potent malonyl CoA and the very high IC 50 of PHX (>100 QM in a expression system) 49 (Table 1) The second scenario for chronic PHX accumulation, and in our view the most likely mechanism that reconciles the low potency of PHX for CPT61 with its actions on this target and on other ion channels is shown in Figure 2D . In this scheme PHX distribution is heterogeneous and (1) it accumulates in the membrane, (2) it interacts directly with CPT61
and (3) within 30 days of drug administration (median 8.5 days). 112 Moreover, although the PHX accumulation in these tissues was directly correlated with plasma concentration of drug and length of therapy there was no evidence of saturability of uptake over the time of study. 112 In a more recent follow6up, the conclusion of Chong and colleagues that PHX does exhibit saturability is not supported by their data (see 103 , Fig 2A and B) . Given these observations, it is difficult to conceive of how long6term PHX administration, even with maintenance of plasma concentrations of the drug at around 1 QM, would not lead to the steady accumulation of toxic levels of PHX. However, one of the authors of this article (ZY) has been treating some HF patients with PHX for over ten years; this chronic administration of PHX is well tolerated and the symptomatic improvements are substantial. Clearly, there are factors that affect PHX tolerance and accumulation that remain incompletely understood.
Finally, one commonly overlooked feature of CPT61 is its widespread tissue distribution. CPT61 is expressed at lower levels in the heart than in other tissues including 49 The issues considered above would presumably apply equally in these tissues and the reported patterns of hepato6, neuro6 and gastrotoxicity are consistent with this idea.
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In this article we have considered issues relating to the chemistry, mechanism of action, tissue accumulation and clinical benefits of PHX. An improved understanding of PHX drug safety and monitoring has underpinned its use in patients with HF and the evidence for its therapeutic efficacy in this context is strong. However, the disparate clinical endpoints following PHX administration in HF arising from distinct aetiologies (e.g. ischaemic6 versus non6ischaemic HF) suggest that the mechanism of action of PHX is complex and not fully understood.
The more recent literature is dominated by the concept that the beneficial effects of PHX are due primarily to its inhibition of myocardial CPT61. Contrary to this dogma, having reviewed all the available evidence, including key patents relating to the clinical usage of PHX and detailed studies of drug6target interactions, we suggest that it is very unlikely that the effects of PHX are due to CPT61 inhibition. Furthermore, over the last twenty years or so the preoccupation with CPT61 as the most relevant target of PHX has overshadowed a substantive body of older, but very credible evidence, for PHX affecting the extra6cardiac circulatory system. It is entirely likely that the therapeutic benefits of PHX in HF are due to combined cardiac and vascular effects (e.g. vasodilation).
The robustness of some of the statements made regarding PHX and CPT61 inhibition is at stark odds with the limited evidence supporting such a mechanism that can be found in the literature. In a recent and detailed analysis of CPT61 inhibitor chemistry, Ceccarelli effectively debunked the idea that perhexiline is a physiologically relevant CPT61 inhibitor. 49 However, we cannot completely exclude the possibility that minor effects of PHX on CPT61
underpin disproportionately large effects on myocardial function, especially since there is massive accumulation of the drug in atrial and ventricular tissue. To reconcile these The linked nature of the composite systems involved in metabolic regulation (i.e. the complex synchronization of ion handling, metabolite sensing, substrate utilization, energy supply6and6demand) means that reconciling any effects on altered energy metabolism with the specific effects on discrete molecular targets is extremely difficult. With this in mind, the evidence that PHX effects are mediated by its actions on a multiple ion channels and other cellular components that impinge on aspects of cellular metabolism is more convincing (Table 1) . In Figure 2D , we propose a scheme which considers the effects of PHX via 1) the inhibition of surface membrane ion channels via low levels of free drug in the cytoplasm and 2) accumulation in mitochondrial membranes which leads to a highly localized concentration of drug in the vicinity of CPT61 resulting in its partial inhibition. In summary, we suggest that due to its physico6chemical properties, PHX is a drug of low potency, low specificity and low selectivity. As a result, the pleiotropic actions of PHX on a diverse range of molecular targets, some of which remain to be properly defined, contribute to its therapeutic benefit in HF. 
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(D) Heterogeneous distribution of PHX via partitioning of neutral and cationic species of drug into mitochondrial membranes which promotes high localized concentrations around CPT61.
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